<i>BTLA</i> promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma
<i>BTLA</i> promoter hypomethylation serves as a significant biomarker for favorable prognosis and enhanced response to ICB therapy in melanoma. The developed qMSP assays for cg24157392 and cg03995631 accurately quantified methylation levels and demonstrated their potential for clinical application in patient stratification and personalized immunotherapy.
Authors
- C. Cameron Yin (ORCID: https://orcid.org/0000-0001-6630-4128)
- Chenxi Zheng (ORCID: https://orcid.org/0000-0003-3182-7206)
- Miao Yu (ORCID: https://orcid.org/0000-0002-6175-0169)
- Yihui Ma (ORCID: https://orcid.org/0009-0004-5649-6903)
- Guozhong Jiang (ORCID: https://orcid.org/0000-0001-6306-726X)
- Minglei Yang (ORCID: https://orcid.org/0000-0001-9957-7608)
- Chongli Zhang
- Peiyi Xia
- Longfei Tang
- Qingfang Han (ORCID: https://orcid.org/0000-0001-7690-3466)
- Shenglei Li (ORCID: https://orcid.org/0000-0003-1966-3536)
- Wencai Li
- Yu Pu (ORCID: https://orcid.org/0009-0009-1169-6916)
Institutions
- Henan Academy of Sciences (CN)
- Henan Provincial People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-009841
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Zhengzhou University
- First Affiliated Hospital of Zhengzhou University